



ANTEO SHAREHOLDER INFORMATION SESSIONS

For Immediate Release:

December 4, 2015

December 4 2015 – Anteo Diagnostics (ASX: ADO) (Anteo) is pleased to invite shareholders to attend one of the following information sessions to discuss the acquisition of DIAsource ImmunoAssays SA, and recently announced funding package.

Shareholder briefing events:

Details of the briefing sessions are below. Shareholders wishing to register interest in attending one of the events, should note their RSVP with Margo Buckton via info@anteodx.com or +61 7 3219 0085 by COB Tuesday, 8 December 2015. At the time of RSVP, please provide the following: name, email, contact number and which briefing session is of interest.

Brisbane:	Wednesday, 9 December, 4:00-6:00pm: Grant Thornton, King George Central, Level 18, 145 Ann Street, Brisbane
Sydney:	Thursday, 10 December, 4:00-6:00pm: Grant Thornton, Level 17, 383 Kent Street, Sydney
Melbourne:	Friday, 11 December, 4:00-6:00pm: Grant Thornton, The Rialto, Level 30, 525 Collins Street, Melbourne

Webcast Q+A session:

For those shareholders unable to attend the information sessions in person, Anteo will hold a question and answer session with Anteo CEO, Dr Geoff Cumming and DIAsource ImmunoAssays SA Chairman, Mr Rolf Sickman on:

Wednesday, 9 December between 11:15am – 12:00pm, Australian Eastern Daylight Time (10:15am Brisbane time).

Shareholders will be invited to submit questions through the webcast interface during the Q+A session.

To attend the session, please visit: <http://goo.gl/TOZNng> to access the webcasting platform in time for an 11:15am AEDT start.

For further information, see our website (www.anteodx.com) or contact the persons outlined below.

Company	Media and Investor Relations
Dr. Geoff Cumming, Chief Executive Officer T: + 61 7 3219 0085	Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au T: + 61 411 117 774
Richard Martin, Chief Financial Officer T: + 61 7 417 229 810	



anteo diagnostics

About Anteo Diagnostics

Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the lifesciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.

The Anteo group owns a patented nanoglue technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests.

This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company's target markets, due to its ability to revolutionise the way scientists work.

While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being conducted into the viability of this battery product.

For more information, please visit www.anteodx.com.